“…There has been limited research on the access and use of genetic technologies among diverse patients ( Canedo et al, 2019 ; Kaphingst et al, 2019 ), particularly with Latinx patients ( Canedo et al, 2020 ; Chavez-yenter et al, 2021a ). For example, people from racial and ethnic minority groups are often interested in testing ( Kaphingst et al, 2015 ; Hay et al, 2019 ; Turbitt et al, 2019 ), but have lower access to and use of cancer genetic services in the US ( Hall and Olopade, 2005 ; Hall and Olopade, 2006 ; Fisher et al, 2019 ), even when cost barriers are minimized ( Alford et al, 2011 ). These disparities have been linked to both individual-level (e.g., lower knowledge) ( Singer et al, 2004 ; Pagan et al, 2009 ; Kinney et al, 2010 ; Bloss et al, 2018 ; Canedo et al, 2019 ) and system-level factors (e.g., unmet needs for discussion of testing with providers) ( Peters et al, 2004 ; Singer et al, 2004 ; Jagsi et al, 2015 ; Kaphingst and Goodman, 2016 ; Roberts et al, 2019 ; Southwick et al, 2020 ).…”